All contributors
Onconephrology contributor
Izzedine, Hassan
Primarily Onco-nephrology (general)#33 of 47 recognized
- #4 in Onco-nephrology (general)
- #4 in Anti-VEGF / TKI renal effects
33
Clinical papers
920
Citations (iCite)
17 / 13
First / senior author
2005–2026
Active years
Output over time
Clinical corpus papers per year — peak 5 in 2017.
- 2005: 1 paper
- 2007: 1 paper
- 2011: 1 paper
- 2012: 1 paper
- 2014: 3 papers
- 2015: 4 papers
- 2016: 3 papers
- 2017: 5 papers
- 2020: 2 papers
- 2021: 4 papers
- 2022: 1 paper
- 2023: 3 papers
- 2024: 2 papers
- 2026: 2 papers
20052026
Subfield mix
Clinical papers by onconephrology subfield (a paper can count in more than one).
Onco-nephrology (general)14
Anticancer drug nephrotoxicity14
Anti-VEGF / TKI renal effects11
Myeloma cast nephropathy4
MGRS & paraprotein kidney disease2
Checkpoint-inhibitor kidney injury2
Tumor lysis & electrolytes1
Frequent collaborators
Other recognized contributors who most often share corpus papers with Izzedine (shared-paper count).
Agents they study
Catalog agents whose clinical kidney literature lists Izzedine among the leading contributors.
Verify
Representative recent papers, and this author’s full PubMed bibliography.
A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,329-article corpus (regenerated 2026-08-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.